However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 million (around $16 million ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

American actor and film-maker Daniel Wu used the recent Chinese New Year holiday to catch up with an old mentor and good friend, Hong Kong action star Jackie Chan. Wu, 50, who first made his name ...

Axed Formula 1 flop Nikita Mazepin will launch a boxing career later this year as he rebrands himself as a "hybrid athlete". The Russian racer rose to prominence when he was signed for the 2021 ...